Clustering based on adherence data by Kiwuwa-Muyingo, Sylvia et al.
METHODOLOGY Open Access
Clustering based on adherence data
Sylvia Kiwuwa-Muyingo
1,2*, Hannu Oja
1, Sarah A Walker
3, Pauliina Ilmonen
1, Jonathan Levin
2, Jim Todd
4
Abstract
Adherence to a medical treatment means the extent to which a patient follows the instructions or
recommendations by health professionals. There are direct and indirect ways to measure adherence which have
been used for clinical management and research. Typically adherence measures are monitored over a long follow-
up or treatment period, and some measurements may be missing due to death or other reasons. A natural
question then is how to describe adherence behavior over the whole period in a simple way. In the literature,
measurements over a period are usually combined just by using averages like percentages of compliant days or
percentages of doses taken. In the paper we adapt an approach where patient adherence measures are seen as a
stochastic process. Repeated measures are then analyzed as a Markov chain with finite number of states rather
than as independent and identically distributed observations, and the transition probabilities between the states
are assumed to fully describe the behavior of a patient. The patients can then be clustered or classified using their
estimated transition probabilities. These natural clusters can be used to describe the adherence of the patients, to
find predictors for adherence, and to predict the future events. The new approach is illustrated and shown to be
useful with a simple analysis of a data set from the DART (Development of AntiRetroviral Therapy in Africa) trial in
Uganda and Zimbabwe.
Introduction
Adherence is defined as the extent to which patients fol-
low instructions for prescribed treatment necessary to
achieve the full treatment benefits [1]. Treatment adher-
ence is known to affect the outcome, but adherence
behavior differs not only between patients, but also over
time [2]. Also there is no standard measure of adher-
ence, and different adherence measures (variables) are
used in different settings and for different treatments
[3]. For chronic diseases requiring continuous adherence
to treatment a single measure is rarely useful, and one
should use combined measures of adherence and con-
sider both mean adherence and the variability in adher-
ence over time [4].
To be clinically relevant, adherence measures should
naturally be prominent predictors for future outcomes.
With anti-retroviral therapy (ART) for HIV infection,
some patients maintain viral suppression and achieve
good outcomes with moderate levels of adherence to
the newer drugs (boosted protease inhibitor and nonnu-
cleoside reverse transcriptase inhibitors) [5]. However,
good adherence is needed to minimise the potential for
the emergence of resistance strains of the virus, and to
support maximal survival benefit in the long-term [6].
In the analysis of adherence data we often use adher-
ence as a predictor of future outcomes. In assessing the
effect of an intervention, measures of adherence are also
valuable in describing how well the intervention is
received (which may change over time). One therefore
wishes to understand and describe in a natural way the
relationships
explanatory variables → adherence → responsevariables
For example, in HIV infection several predictors of poor
adherence to anti-HIV drugs can be found, including low
socio-economic status of the patient [7], low education [8],
regimen complexity [9], dosing frequency, cost of drugs
and transport [10]. Non-adherence has also been associated
with the drug regimen, personal factors, stigma, side
effects, and travel away from home [11]. The impact of dif-
ferent patterns of adherence differs by drug class [5,12,13].
Various statistical methods have been used to predict
adherence. Linear regression, logistic regression, or multi-
nomial models have been used when adherence is
expressed as a percentage, as a dichotomized variable
(good vs poor adherence), or as a categorical or categorized
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ginal models have been used for an analysis of repeated
measures adherence data [14].
In the HIV studies, for example, adherence to ART is
an important predictor of mortality, disease progression
and virological failure [3,5,15]. Poor adherence to ART
raises public health concerns of increased prevalence of
disease, more potential for transmission of drug resistant
virus to uninfected partners and minimizes the cost ben-
efit of ART. However one difficulty with the analysis of
adherence data is how to model the dynamic changes in
adherence over time, and how to relate changes in adher-
ence to patient characteristics, and to patient outcomes.
However since adherence is a dynamic and complex
human behavior, the key is not so much the individual,
observed values themselves, as whether we can character-
ize the underlying behavior of the patient outside the ART
clinic from the observed pattern of reported adherence. In
an alternative approach patient adherence measures are
seen as a stochastic process, as described by Girard at al,
Wong et al, and Sun et al [16], [17] and [18]. Stochastic
models have the advantage of taking into account variabil-
ity in adherence over time, being able to incorporate and
distinguish missing data, and flexibility over the type of
adherence measure used at each time point.
In our approach to develop new statistical tools to
characterize and understand the adherence behavior of
the HIV patients treated with ART, and to illustrate the
use of these tool with real data. To do this the adher-
ence measures at each time point are first categorized to
av a r i a b l ew i t hf i n i t en u m b e ro fv a l u e so r“states”.
Repeated measures over time are then analyzed as a
Markov chain of order 1, and the transition probabilities
between the states are thought to describe the behavior
of a patient. The patients are then clustered using their
estimated transition probabilities between the various
adherence states. These natural clusters can be used to
describe variation in adherence, to find predictors for
adherence, and to predict future disease progression or
other outcomes. The new approach is illustrated with a
simple analysis of a data set from the Development of
Antiretroviral Therapy in Africa (DART) trial in Uganda
and Zimbabwe (see http://www.ctu.mrc.ac.uk/dart). We
compare the predictive powers of different models for
mortality with adherence as a continuous and categori-
cal explanatory variable under different Markov chain
model assumptions. The comparisons are made using
the ROC curves and areas under the ROC curves.
The paper is organized as follows. In Section 2 we
describe the repeated adherence measurements on each
individual as a Markov chain, and assume that the
population consists of a finite number of clusters of
patients with the same transition probabilities. In Sec-
tion 3 the hierarchical clustering procedure based on
the transition probabilities is described. Section 4 pro-
vides an example of DART trial data. We use three dif-
ferent models (repeated measurements are (i)
independent and identically distributed, or distributed
according to a (ii) homogeneous or (iii) non-homoge-
neous Markov chain model) to analyse the data, we
describe and interpret the clusters and compare their
ability to predict mortality. A discussion of the relative
merits of this new approach is given in section 5.
Adherence seen as a Markov chain
We assume that the adherence is measured by a discrete
variable with finite number of possible values 1, ..., S.
The values are here called states. For each individual the
states are recorded at T time points 1, ..., T.T h e
observed states are then denoted by X1, ..., XT , and the
whole process can be seen as one classificatory variable
with S
T classes or profiles. Note that if the adherence
measurements are continuous or multivariate, they must
first be categorized for the analysis. Note also that miss-
ing data at some time point can be treated as one of
the states.
The adherence measurements over time points 1, ..., T
are usually combined by averaging over the entire per-
iod to give the estimated probabilities (proportions) of
being in each state,
ˆ Ps =
1
T
T  
t=1
I(Xt = s), s = 1,...,S
where I (Xt = s)=1i fXt = s and zero otherwise. Note
that, if X1, ..., XT are independent and identically distrib-
uted categorical random variables, this would be a suffi-
cient way to describe the adherence behavior over the
follow-up period. In this paper, we rather see the adher-
ence as a process, as a (homogeneous) Markov chain
with the transition probabilities between states
pij = P(Xt+1 = j|Xt = i), i,j ∈{ 1,...,S}
See Chapter 6 in [19], for example. Matrix
P =( pij)
is then called the transition matrix. A natural estimate
of pij,i f
 T−1
t=1 I(Xt = i) > 0,i s
ˆ pij =
 T−1
t=1 I(Xt = i,Xt+1 = j)
 T−1
t=1 I(Xt = i)
A more complicated, and sometimes more realistic
model to describe the adherence behavior is to use the
Markov chain of order 2 with transition probabilities
pijl = P(Xt+2 = l|Xt = i,Xt+1 = j), i,j,l ∈{ 1,...,S}.
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chain is non-homogeneous in the sense that the transi-
tion probabilities change at a time point t1 so that the
transition probabilities are given by two S × S matrices,
say,
P1 for t = 1,...,t1 and P2 for t = t1 + 1,...,T.
Clustering based on Markov chain approach
In the paper we assume that the adherence behavior of
each individual is a Markov chain with unknown transi-
tion probabilities. We also assume that the population
of the patients can be divided into subpopulations or
clusters such that within a cluster the transition prob-
abilities are the same. The cluster memberships can
then be used as a categorical variable in further analysis.
The unknown cluster memberships must naturally be
estimated from the data.
The problem then is how to identify or estimate the
clusters using the measurements
X1,...,XT.
We explain the procedure in the case of the homoge-
neous Markov chain model. First we find the matrix
Q =( qij) with elements
qij =
1
T − 1
T−1  
t=1
I(Xt = i,Xt+1 = j), i,j = 1,...,S
and then vectorize Q to get a S
2-variate observation
vector
Z = vec(Q).
The vector Z is thus obtained by stacking the columns
of Q on top of each other. Note that the estimates of
the transition probabilities in P can be obtained by Q
just by dividing each row of Q by its row sum. To avoid
the possible divisions by zero we use Q instead of P in
our analysis. The observed vectors Z are then used
instead of the original X1, ..., XT to cluster the data.
I nt h ef o l l o w i n gw eu s et h eS
2-variate observations
Z1, ..., ZN to cluster the N individuals in the data. (The
vectors Zi, i =1 ,. . . ,N , are in fact lying in the (S
2 -1 ) -
variate space as the sum of the components is one. We
however prefer to use the whole vector Zi in our analy-
sis instead of any choice of a subvector.) The marginal
variables are often standardized for the cluster analysis
but that is not natural here; the marginal variables are
here probabilities and therefore already on the same
underlying scale. We use the hierarchical clustering
technique which starts with N clusters (individuals) and
then iteratively joins the two most similar clusters until
there is just a single cluster. This gives a tree of clusters
with can be illustrated with a dendrogram; one can then
cut the tree to have a suitable number of clusters. The
clusters should not be too small and they should have
relevant interpretations. Natural interpretations may be
obtained via joint conditional transition probabilities in
the cluster. A measure of dissimilarity or distance
between classes is needed for the clustering procedure.
Let two distinct index sets I and J,w i t hI, J ⊂ {1, ..., N},
give the indices corresponding to two clusters, and let nI
and nJ be the corresponding cluster sizes. The popular
Ward’s minimum variance method of linkage compares
the between and within squared Euclidean distances
with
d(I,J)=
 
i∈I∪J
   Zi − ¯ Z
   2 −
 
i∈I
   Zi − ¯ ZI
   2 −
 
j∈J
   Zj − ¯ ZJ
   2
where ¯ Z , ¯ ZI and ¯ ZJ are the sample mean vectors
over the subsets with indices in I ∪ J , I and J, respec-
tively. See Chapter 7 in [20]. R software was used in the
practical analysis of data.
If X1, ..., XT are identically and independently distribu-
ted then the clustering should be based on a S-vector
Z =( P1 , ..., PS )o n l yw h e r ePs =[ 1 / T]
 T
t=1 I(Xt = s), s
= 1, ..., S. In case of the non-homogeneous Markov
chain, one may consider two matrices of estimated
probabilities, Q1 and Q2, which correspond to measure-
ments at time points 1, ..., t1 and t1 +1 ,. . . ,T ,r e s p e c -
tively. The clustering algorithm is then based on the
2S
2-vector Z = vec(Q1,Q 2). The interpretations for the
clusters can then made using two matrices of transition
probabilities, P1 and P2 . In our application, the change
point t1 is assumed to be fixed and known.
An example: The DART trial in Uganda and Zimbabwe
The data and the problem
We illustrate the clustering procedure and its use with a
cohort data set of 2960 participants in the DART trial
in Uganda and Zimbabwe. The trial started in January
2003, and the patients were followed until the end of
December 2008. Participants’ adherence to the treat-
ment was assessed by pill counts and a structured ques-
tionnaire administered at each scheduled 4-weekly clinic
visit. Participants were asked questions on whether they
had missed any dose in the last month, were late for the
visit, had forgotten to take any dose at the weekend or
missed any ART in the four days prior to the clinic
visit. Drug possession ratio (DPR) previously defined as
the days’supply of drugs delivered minus the days’supply
of drugs returned divided by the number of days
between clinic visits, assuming that ART was used con-
tinuously throughout the period between the clinic visits
was obtained from clinic based pill counts [21]. Also
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drawals from the study were recorded.
The objective of this analysis was thus to find groups
of DART patients with a similar adherence behavior
(same proportions of being in each state, or same transi-
tion probabilities in homogeneous or non-homogeneous
Markov chains) during the first year of the follow-up.
We then considered whether the cluster membership
c o u l db ee x p l a i n e db ya g eo rg e n d e r( c h i - s q u a r et e s t s
for independence) and whether the risk of death during
the second and third year of the follow-up was different
in different clusters (chi-square goodness-of-fit tests,
logistic analysis).
Adherence variables in this study
In this study we consider the adherence data collected
during the first year of the follow-up period (T = 12 vis-
its). Analysis was restricted to the N = 2960 patients
who were alive at the end of the first year of the trial, as
described in Muyingo et al [21]. We have previously
shown that of all self reported measures, ‘missed any
dose in the last month’ most strongly associated with
Viral load [21]. The adherence patterns of patients alive
at 12 months were later used to predict the mortality
during the second and third year. Adherence data were
missing at a visit either because the patient (i) totally
missed a visit, or (ii) attended but did not complete the
adherence questionnaire. For the illustration of our
approach here we only use a simple binary variable
‘missed any dose in the last month’ with the third possi-
bility of missing data for this question for any reason.
We then use the Markov chain with S = 3 states,
0( poor), 1 (good), and 9( missing)
Note that the adherence values (X1,. . . ,XT )m a yb e
seen as one classificatory variable with S
T =3
12 = 531,
441 classes (profiles). Clustering is a way to reduce the
number of classes in a rational way.
The rational and efficient use of the observed values
X1, ..., XT in the clustering naturally depends on the true
statistical model. In the following we consider and com-
pare three different models, namely,
(M1) the i.i.d. model, that is, X1,. . . ,XT identically and
independently distributed,
(M2) the homogeneous Markov chain model, and
(M3) the non-homogeneous Markov chain model.
In the model (M3) we assume that the change point is
at six months time. Note that the models are nested so
that (M1) ⇒ (M2) ⇒ (M3). Likelihood ratio tests can be
used to discriminate between the models.
To illustrate the differences between the approaches,
consider three individuals, i1, i2,a n di3, with the follow-
ing observed values of X1, ..., X12.
i1 :9 ,9 ,9 ,0 ,0 ,0 ,0 ,0 ,1 ,1 ,1 ,1
i2 :9 ,0 ,1 ,1 ,1 ,9 ,1 ,0 ,0 ,0 ,0 ,9
i3 :9 ,1 ,0 ,0 ,0 ,9 ,0 ,0 ,1 ,1 ,1 ,9
The profiles of the individuals look very different but,
if we assume that the model (M1) is true and therefore
use estimated probabilities of being in each state (suffi-
cient statistic), the we get
Pi1 = Pi2 = Pi3 = (0.417,0.333,0.250) 
and the three individuals are treated identically in the
analysis (zi1 = Zi2 = Zi3).
If one assumes that the second model (M2) is true
then one should use the matrix Q =( qij) with elements
qij =
1
T − 1
T−1  
t=1
I(Xt = i,Xt+1 = j), i,j = 1,...,S,
(a sufficient statistic) to condense the data. For the
three individuals we then get
Qi1 =
⎛
⎜
⎝
0.364 0.091 0.000
0.000 0.273 0.000
0.091 0.000 0.182
⎞
⎟
⎠ and
Qi2 = Qi3 =
⎛
⎜
⎝
0.273 0.091 0.091
0.091 0.182 0.091
0.091 0.091 0.000
⎞
⎟
⎠,
and individuals i2 and i3 again get the same value Z=
vec(Q). Finally, in the third model (M3), the three values
of Z = vec(Q1, Q2) are different, namely,
Zi1 = (0.4,0.0,0.2,0.0,0.0,0.0,0.0,0.0,0.4,0.2,0.0,0.2,0.3,0.0,0.0,0.0,0.0) ,
Zi2 = (0.0,0.0,0.2,0.2,0.4,0.0,0.0,0.2,0.0,0.6,0.2,0.0,0.0,0.0,0.0,0.2,0.0,0.0) ,a n d
Zi3 = (0.4,0.2,0.0,0.0,0.0,0.2,0.2,0.0,0.0,0.2,0.0,0.0,0.2,0.4,0.0,0.0,0.2,0.0) ,
Depending on the chosen model one then uses the
adherence variable
Z = P(model (M1)),Z = vec(Q)( model (M2)),or
Z = vec(Q1,Q2) (model (M3)),
i nt h ea n a l y s i s .T h ev a r i a b l ei st h e n3 - ,9 -o r1 8 - v a r i -
ate, respectively.
Clustering based on the models (M1), (M2), and (M3)
We use hierarchical clustering as explained in Section.
The clustering is first based on the 3-variate variable Z
= P , and the number of clusters was chosen to be six.
The probabilities of being in states 0,1, and 9 in each
cluster are reported in Table 1. Cluster 1, for example,
has the highest proportion for missing data but the pro-
portion for good behavior is also high 83%. Cluster 5 is
the poorest one as the proportion for good behavior is
only 43%. The last cluster 6 consists of 891 optimally
behaving patients.
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Z = vec(Q) and the homogeneous Markov chain model.
For the comparison we use again six clusters here. The
transition probabilities between states 0, 1, and 9 in six
clusters are reported in Table 2. The probabilities in the
table for cluster 2, for example, are read as follows. 52%
of those patients who reported good adherence in the
previous month achieved good adherence also in this
month, 31% of those having missing data in previous
month reported good adherence in this month, and so
on.
Cluster 2 is clearly the poorest one, as the proportion
maintaining good adherence from one month to the
next is the lowest. Patients in cluster 6 behave in an
optimal way.
Third, we also clustered the data using 18-variate vari-
able Z = vec(Q1, Q2) based on the heterogeneous Mar-
kov chain model. The conditional transition
probabilities were then allowed to be different over dif-
ferent periods (with a change point at six months). The
estimated transition probabilities with six clusters are
given in Table 3. The clusters can be roughly character-
ized in the following way.
￿ Cluster 1: Good adherence - getting worse
￿ Cluster 2: Poor adherence with missing data - get-
ting slightly better
￿ Cluster 3: First poor with some missing data - then
very good
Table 1 The probabilities of being in state 0, 1, and 9 in
six clusters based the i.i.d. model (M1)
State
019Σ
Cluster 1 (n = 469) .065 .829 .107 1.000
Cluster 2 (n = 426) .280 .688 .032 1.000
Cluster 3 (n = 360) .167 .833 .000 1.000
Cluster 4 (n = 618) .083 .917 .000 1.000
Cluster 5 (n = 196) .489 .426 .085 1.000
Cluster 6 (n = 891) 0 1 0 1.000
Table 2 Conditional transition probabilities in six clusters
based on homogenous Markov chain model (M2)
Cluster 1 (n = 301) Cluster 2 (n = 281)
019Σ 019Σ
0 0 1 0 1.000 0 0.425 0.523 0.052 1.000
1 0.008 0.950 0.042 1.000 1 0.436 0.516 0.049 1.000
9 0 1 0 1.000 9 0.235 0.307 0.458 1.000
Cluster 3 (n = 463) Cluster 4 (n = 596)
019Σ 019Σ
0 0.177 0.765 0.057 1.000 0 0.253 0.723 0.024 1.000
1 0.073 0.871 0.056 1.000 1 0.207 0.770 0.023 1.000
9 0.131 0.652 0.217 1.000 9 0.222 0.684 0.094 1.000
Cluster 5 (n = 469) Cluster 6 (n = 850)
019Σ 019Σ
0 0 1.000 0 1.000 0 . . . .
1 0.091 0.909 0 1.000 1 0 1.000 0 1.000
9. . . .9. . . .
Table 3 Conditional transition probabilities in six clusters
based on heterogeneous Markov chain model (M3)
Cluster 1 (n = 519)
Period 1 Period 2
019 Σ 019 Σ
0 0.027 0.960 0.133 1.000 0 0.095 0.866 0.039 1.000
1 0.034 0.953 0.013 1.000 1 0.115 0.824 0.061 1.000
9 0.117 0.860 0.023 1.000 9 0.051 0.800 0.149 1.000
Cluster 2 (n = 309)
Period 1 Period 2
019 Σ 019 Σ
0 0.431 0.526 0.043 1.000 0 0.403 0.549 0.048 1.000
1 0.497 0.458 0.045 1.000 1 0.279 0.672 0.049 1.000
9 0.264 0.373 0.364 1.000 9 0.123 0.352 0.519 1.000
Cluster 3 (n = 408)
Period 1 Period 2
019 Σ 019 Σ
0 0.275 0.684 0.041 1.000 0 0.000 1.000 0.000 1.000
1 0.246 0.690 0.063 1.000 1 0.015 0.978 0.007 1.000
9 0.226 0.598 0.177 1.000 9 0.067 0.933 0.000 1.000
Cluster 4 (n = 441)
Period 1 Period 2
019 Σ 019 Σ
0 0.285 0.681 0.035 1.000 0 0.191 0.781 0.028 1.000
1 0.163 0.799 0.039 1.000 1 0.273 0.697 0.030 1.000
9 0.202 0.556 0.242 1.000 9 0.261 0.620 0.120 1.000
Cluster 5 (n = 433)
Period 1 Period 2
019 Σ 019 Σ
0 0.000 1.000 0.000 1.000 0 . . . .
1 0.118 0.853 0.029 1.000 1 . 1.000 . 1.000
9 0.000 1.000 0.000 1.000 9 . . . .
Cluster 6 (n = 850)
Period 1 Period 2
019 Σ 019 Σ
0. . . .0. . . .
1 . 1.000 . 1.000 1 . 1.000 . 1.000
9. . . .9. . . .
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changes
￿ Cluster 5: First good - then optimal
￿ Cluster 6: Optimal in both periods
Table 4 gives a cross-tabulation of cluster member-
ships in the three clustering based on models (M1),
(M2), and (M3). One can see that the groups are genu-
inely different and, as seen from the description of clus-
ters above, the groupings based on (M2) and (M3)
describe the adherence behavior in more versatile ways.
Adherence clusters, predictors and explanatory variables
As an illustration of the use of the clusters in a further
analysis, we considered the relationship between age and
sex and adherence which was categorized using clusters
based on non-homogeneous Markov chain model (M3).
We also considered how the risks of death in the second
and third year of follow-up were associated with adher-
ence behavior during the first year. We thus follow the
scheme
gender, age → adherence → death
The results in the analyses for clusters coming from
heterogeneous Markov chain model (Z =v e c ( Q1, Q2))
are given in Tables 5 and 6. No difference was found
between the proportions of women or between the age
distributions. There were 100 deaths in the second and
third year, individuals in cluster 2 were 2.72 (95%
CI:1.42 to 5.18) times more likely to die and in cluster 4
were 2.08 (95% CI:1.42 to 5.18) times more likely to die
as compared to Cluster 6 with optimal adherence. Indi-
viduals in Clusters 1 and 3 were 1.41 (95% CI:0.72 to
2.71) and 1.47 (95% CI:0.72 to 2.92) times more likely to
die whilst in cluster 5, were 0.88 (95% CI:0.72 to 2.71)
times likely to die compared to the optimal cluster 6.
Adjusting for age and sex did not change the OR esti-
mates. (Age and sex are not confounding factors in this
analysis.) Again, R software was used in these analyses.
Finally, we also compared the categorical cluster vari-
ables based on the three models (M1), (M2), and (M3)
as predictors of mortality during the second and third
year of ART. If linear predictor b’Zi with the rule b’Zi
>c is used as a predictor for the death of individual i,
then the receiver operating characteristic (ROC) curve is
a graphical tool for illustrating the trade off between the
false negative (sensitivity) and false positive rates (speci-
ficity) for all possible cut off points c,a n dt h ea r e a
under the ROC curve is a numerical measure of that.
There are no big differences between the predictive
powers of the three categorical cluster variables based
on models (M1), (M2), and (M3) as seen in Figure 1.
For the comparison, also the ROC curves from the
Table 4 Contingency tables for cluster categories when
clusters are based on (a) models (M1) and (M2), (b)
models (M1) and (M3), and (c) (M2) and (M3)
(a) (M2)
123456
(M1) 1 146 1 250 72 0 0
2 0 11 6 309 0 0
3 0 0 172 188 0 0
4 114 0 35 0 469 0
5 0 169 0 27 0 0
6 4 1 0000 8 5 0
(b) (M3)
123456
1 187 14 116 89 63 0
2 5 127 82 212 0 0
3 63 1 187 109 0 0
4 223 0 19 6 370 0
5 0 167 4 25 0 0
6 4 1 0000 8 5 0
(c) (M3)
123456
(M2) 1 124 0 0 0 177 0
2 0 223 0 58 0 0
3 158 2 252 51 0 0
4 24 84 156 332 0 0
5 213 0 0 0 256 0
6 00000 8 5 0
Table 5 Clusterwise mortality in the second and third
year on ART, proportion of women and proportion of
patients in three age groups
Age at ART initiation
n deaths women 18-35 35-45 45+
Cluster 1 (n = 519) .033 .65 .41 .42 .17
Cluster 2 (n = 309) .061 .62 .39 .42 .19
Cluster 3 (n = 408) .034 .65 .41 .42 .16
Cluster 4 (n = 441) .048 .65 .41 .43 .16
Cluster 5 (n = 433) .020 .65 .37 .45 .15
Cluster 6 (n = 850) .024 .65 .40 .46 .15
Six clusters are based on the heterogeneous Markov chain model.
Table 6 Estimated odds ratios (OR) with 95 percent
confident intervals to compare the risk of deaths in
different clusters, also adjusted for age and sex
OR 95% CI Adjusted OR 95% CI
Cluster 1 1.4 (0.72, 2.71) 1.4 (0.71, 2.68)
Cluster 2 2.7 (1.42, 5.18) 2.7 (1.41, 5.17)
Cluster 3 1.5 (0.72, 2.93) 1.5 (0.71, 2.91)
Cluster 4 2.1 (1.11, 3.89) 2.1 (1.10, 3.87)
Cluster 5 0.9 (0.38, 1.90) 0.88 (0.38, 1.90)
Cluster 6 1 1
Cluster 6 serves as a reference class. The clusters are based on the
heterogeneous Markov chain model.
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Z = P , Z = vec(Q), and Z = vec(Q1, Q2)u s e da sl i n e a r
predictors in the conventional logistic regression model
are given in Figure 2. (Of course the linearity assump-
tion may not be realistic.) The predictive powers in
these cases were again very similar. This may be due to
t h ev e r ys h o r tf o l l o w - u pt i m eo f1 2m o n t h st oa s s e s s
adherence.
Discussion
The main motivation of this paper was to develop and
illustrate new statistical tools to characterize and
understand the adherence behavior of the HIV patients
treated with ART, and to illustrate these tools with
data from the DART study. The Markov chain model
is perhaps the simplest model for dependent categori-
cal repeated measurements. In this work, estimated
proportions and transition probabilities in a three-state
Markov chain model were used to cluster the indivi-
duals into groups with different adherence patterns.
Transition probabilities represent the dynamics of
adherence to ART, and the non-homogeneous Markov
chain model allows the patients to change their adher-
ence behaviour over time. Relating patient characteris-
tics to transition probabilities may enable a better
understanding of adherence patterns compared to the
traditional methods of just averaging the raw adher-
ence data.
We illustrated the approach using one variable -
“m i s s e da n yd o s eo fA R Ti nt h el a s tm o n t h ” -b u tt h e
approach could be extended to a any number of adher-
ence variables. Several variables can then be used
together to construct the states needed for Markov
chain model. Our approach can naturally be applied to
different data sources (patients diaries, electronic event
monitoring, drug possession ratio %), and to the adher-
ence to several drugs simultaneously. Using different
adherence variables (if not highly correlated) would pro-
duce different clusters with different predictive powers
for mortality. The choice of adherence variables is there-
fore a crucial step, and depends on the data and
application.
In our approach, the adherence observations X1, ..., XT
at time points 1, ..., T , are seen as a realization of a ran-
dom process. Data analysts often implicitly assume that
the observed values X1, ..., XT are independent and iden-
tically distributed (iid). We think that such assumptions
should be explicitly stated, and that it is unrealistic to
assume that there is no dependence and no changes in
distributions of Xi. With our Markov chain model we
have explicitly stated and assumed a certain simple
dependency between the observations. In the paper, we
compare three different models, namely the iid model
(M1), the homogenous Markov chain model (M2), and
the non-homogenous Markov chain model (M3). Note
that both (M1) and (M2) assume that there is no change
in the adherence behavior over the follow-up period. In
model (M3) this is allowed. If we assume constant tran-
sition probabilities over time we may lose information
and important aspects of the phenomenon. It also
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Figure 1 ROC curves for predicting mortality using categorigal
cluster variable based on model (M1) (3 variables), model (M2)
(9 variables) and model (M3) (18 variables).
0 . 00 . 20 . 40 . 60 . 81 . 0
0
.
0
0
.
2
0
.
4
0
.
6
0
.
8
1
.
0
1ŦSpecificity
S
e
n
s
i
t
i
v
i
t
y
3 variables, AUC=0.615
9 variables, AUC=0.615
18 variables, AUC=0.638
Comparing ROC curves
Figure 2 ROC curves for predicting mortality using continuous
Z-variable based on model (M1) (3-variate), model (M2) (9-
variate) and model (M3) (18-variate).
Kiwuwa-Muyingo et al. Epidemiologic Perspectives & Innovations 2011, 8:3
http://www.epi-perspectives.com/content/8/1/3
Page 7 of 10important to note that the three models are nested
within each other, so that the regular likelihood ratio
tests can be used to distinguish between the models;
this will be studied in our future work. In the paper we
are interested in modeling adherence behavior in gen-
eral rather than in modelling the changes in adherence
behavior as in Lazo et al [22]. However, our model (M3)
is flexible enough for modeling the changes as well. In
model (M3), the transition probabilities can naturally be
made to depend on explaining (modifiable) factors; this
is however beyond the scope of this paper.
In our earlier paper [21] we showed that although
adherence looked very high overall in the first year in
DART, this masked an inconsistent adherence behavior
at the individual level. For the illustration and compari-
son of different adherence pr o f i l e sw eg a v ea ne x a m p l e
of three individuals with very different profiles ((9, 9, 9,
0, 0, 0, 0, 0, 1, 1, 1, 1), (9, 0, 1, 1, 1, 9, 1, 0, 0, 0, 0, 9),
and (9, 1, 0, 0, 0, 9, 0, 0, 1, 1, 1, 9)) but similar overall
adherence (measured as proportions). The differences
between the individuals cannot be explained with model
(M1) and not even with model (M2). Only model (M3)
can analyse the differences between these three indivi-
duals. For the DART data set, we found six clusters
based on models (M1), (M2), and (M3). The clusters
were genuinely different with different interpretations.
Also clusters with changing behavior could be found
(which supports the use of model (M3)). Our findings
suggest that different approaches may be potentially use-
ful in practical data analysis, and that overall (mean)
adherence may not be enough when dealing with ART
adherence. We compare the predictive powers of the
procedures based on models (M1), (M2), and (M3) for
mortality with ROC curves. We could not find any big
differences between the procedures, but this may just be
due to the short period for the measurements of adher-
ence. Whilst viral load is of major importance to partici-
pants, this was not done in real-time, so not available
for all participants. Death was also relatively infrequent
in the second and third year (proportion of deaths =
3%) and so the power to distinguish different effects of
M1 from M2 or M3, M2 from M3 was low. However
the fact that M2 and M3 classified people differently
illustrates potential of our approach.
The DART trial has collected data on virological fail-
ures and immunological failures as well. Those outcome
variables will be considered in future analyses looking at
the predictive value of these adherence clusters. We did
not find any significant association between the adher-
ence groups and age or gender. It is possible, however,
that other socio-demographic variables are associated
with the adherence groups. This approach could then be
used in the future to identify individuals at risk of poor
adherence. It is of course important to validate this new
approach against outcomes that are associated with
adherence to ART. In this work, the clustering variable
based on the non-homogeneous Markov model was
seen to be associated with the risk of death in the sec-
ond and third year of ART. Those reporting poor or
less than adequate adherence had a significantly higher
mortality in the second and third year than those that
achieved optimal adherence, with the good and adequate
users somewhere in-between. The worst cluster has the
highest mortality risk.
Our analysis was restricted to those who survived the
first year of the trial [21]. The majority of deaths in the
first year occurred in the first 3 months (50%). The
patients with early deaths did not have the opportunity
to fully demonstrate their adherence behavior. We also
reasoned that poor patient outcome associated with
adherence would likely manifest later in the course of
treatment. We considered mortality during the second
or third year as the outcome that adherence might pre-
dict. The causal pathway is that poor adherence leads to
viral replication in the presence of low levels of drug
which leads to drug resistance which leads to viral
rebound which leads to CD4 decline, and finally leads to
morbidity/mortality. It is precisely this process which
takes several months, and motivates our prediction
model where adherence in the first year predicts mortal-
ity in the second or third year.
B e c a u s ew eh a v eu s e dar e l a t i v e l ys h o r tt i m ep e r i o d
for the assessment of adherence, the vector Z (with
dimensions 3, 9, and 18 in different models) that we use
for clustering seems to have a higher dimension than
the vector of original observations (with dimension 12).
However, the original adherence measurements yield in
fact 3
12 different profiles, and the idea here is to classify
these profiles in a rational way. The transformed vari-
ables Z provide sufficient statistics in different models; if
Z is known then X1, ..., XT does not carry any additional
information on the model. Our clustering procedures
were based on Euclidean distances and Ward’sm i n i -
m u mv a r i a n c em e t h o da st h e ys e e m e dt ow o r kw e l li n
our case. Alternative linkage methods and distance mea-
sures should be used to generate the clusters for the
comparison. In determining the distances between the
individuals we could for example assign different
weights to different transition probabilities. This will be
a part of our future work on the use of stochastic adher-
ence models and their use to predict future events.
It is of course not always clear what population quan-
tities we are estimating when we report the odds ratio
estimates for mortality for the six clusters we have
obtained. The underlying assumption is that the data set
used in the analysis is a random sample from a popula-
tion with six subpopulations having different adherence
behavior, then the cluster memberships (with six
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ships, and the odds ratios using cluster memberships
estimate the unknown odds ratios for the difference in
mortality in the subpopulations. Under the above strict
assumptions one may hope that the estimates are con-
sistent to population values. However, if one does not
believe in this assumption, one can still consider the
predictive power of the whole procedure (area under the
ROC curve) and use that for meta-analysis.
There are several extensions and possibilities to
develop and deepen the analysis of DART trial data:
Another extension to this approach would be to use two
or more measures of reported adherence for the states
in the Markov chain model. Continuous measurements
such as the drug possession ratio could be categorized
and used in the Markov chain model. One could look at
trends over time and/or over a longer period of 3 years.
One could use more states such as lost in the follow-up.
In our analysis the problem of drop-outs did not arise
as all patients who died or were lost to follow-up in the
first year of the trial had been excluded from the dataset
[21]. Only 968(2.7%) clinic visits had missing data, 653
were due to forms not being completed by the adher-
ence nurse and 315 were due to missed visits. These
numbers were small and were not divided further in this
application but could easily be divided if the analysis
required it.
For example in clinical trials, non-response or drop-
out are important outcomes in their own right and
should be distinguished from incomplete forms or poor
documentation. Another extension of the model used
here would be the use of the Markov chain model of
order 2. Statistical tools are needed for the model selec-
tion: Statistical tests and estimates for the change point
in a non-homogeneous Markov chain model, and tests
and estimates for the order of the model. We could
easily build likelihood ratio tests for our nested para-
metric families of distributions. To show whether our
Markov chain fits better than an independence model
and more specifically test for homogeneity; if our non-
homogeneous Markov chain of order 2 fits better than
the homogeneous one.
Our aim in this paper was to develop and illustrate
some new ideas on how to classify patients based on
adherence data using a stochastic model and to illustrate
how this analysis could be carried out on real data.
Further detailed analyses will be undertaken using the
full DART dataset, in which wew i l le x p l o r et h ee x t e n -
sions to the basic model, develop ways of testing differ-
ent models and evaluate factors that influence the
transition probabilities. We believe this may develop a
new way of looking at adherence and in better analysing
adherence data.
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